Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa

NCT05663268 is registered in ClinicalTrials.gov with Services Institute of Medical Sciences, Pakistan as lead sponsor.

NCT NCT05663268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05663268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2022
Completion date
September 30, 2023
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa